about
Effect of temozolomide in patients with metastatic bronchial carcinoids.Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial.Biomarkers and molecular imaging in gastroenteropancreatic neuroendocrine tumors.Design and rationale of TROCADERO: A TRial Of Caffeine to Alleviate DyspnEa Related to ticagrelOr.Bioresorbable Stents in PCI.Growth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major BleedingBiomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet InhibiReal-life clinical outcomes with everolimus eluting platinum chromium stent with an abluminal biodegradable polymer in patients from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR).Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary Disease.Biomarkers for risk stratification of patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention: Insights from the Platelet Inhibition and Patient Outcomes trial.Early diagnosis of acute coronary syndrome.Genome-wide association and Mendelian randomization study of NT-proBNP in patients with acute coronary syndrome.Timing of percutaneous coronary intervention in patients with non-ST-elevation myocardial infarction: a SWEDEHEART study.New Method for Assessing the Effect of Driving Distance to Hospital Care: Using OpenStreetMap Routing in Cardiovascular Research.Large-Scale Phenome-Wide Association Study of Variants Demonstrates Protection Against Ischemic StrokeBioabsorbable polymer everolimus-eluting stents in patients with acute myocardial infarction: a report from the Swedish Coronary Angiography and Angioplasty RegistryCaffeine and incidence of dyspnea in patients treated with ticagrelorBioimpedance and New-Onset Heart Failure: A Longitudinal Study of >500 000 Individuals From the General PopulationNormal radiological lymph node appearance in the thoraxClinical and Genetic Determinants of Varicose VeinsAssessing the Nationwide Impact of a Registry-Based Randomized Clinical Trial on Cardiovascular PracticeSubsequent Event Risk in Individuals With Established Coronary Heart DiseaseAssociation of Chromosome 9p21 With Subsequent Coronary Heart Disease EventsAssociation of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes: A Secondary Analysis of the PLATO Biomarker Study
P50
Q33409946-909586B9-4290-4E49-8B3E-42D061AC8AB9Q34043989-D7C20870-A06C-43AE-BB0D-59DEE99E90D0Q34051127-AB3A92CC-1CA2-49CC-9CF5-F67D4B96F3D5Q35780835-C893A206-2A89-41CB-A43C-CF739423B545Q36055029-B34B6A47-C808-41F8-9931-EF60B3712B79Q36347479-07AEAD3F-0D81-475F-BEA0-26823F6FF80DQ38442214-A0E76FC4-319C-4CF2-966B-6A6CC7F36135Q38764106-44AB8315-6ECF-4415-B651-C2ECFA301D19Q40087064-5606CBA7-536E-46CE-A9E6-BC4BC56C2BF9Q40886109-75371AA7-5E13-4060-BD52-6F21F83F0E5EQ47651343-E9FF1343-AC2F-437D-A26B-38EF8DA713D5Q47715400-DCF5B353-F664-4F3B-919B-D3243EBE37BDQ50017119-BB4C12E5-7E1F-4108-A713-59F16DA9356CQ53094790-969DAAAF-3184-40D1-A79D-95F3F5C7CACAQ57177843-0B8D8E9F-5D0D-4047-8CCD-9D0B650C9996Q88787593-E4290114-F384-42AA-8197-0C7A21C8AE43Q89092892-55988D33-1D35-41FE-954A-5CC9F1ADD87AQ89355282-96E4DBB2-B46A-400B-A651-DAD012794826Q90609979-95A629C9-5CF4-4A46-A477-E0A7059B4D9BQ90632577-34B7EA90-EC41-4946-AB3F-F0433B054181Q92174521-EFBE29CE-6D0A-4C13-8918-40A3CA9AEBCBQ92522162-B1B1808D-B449-455C-A2D1-C5FB444326E8Q92528135-2DB009DF-6FD0-42B8-AB2F-398FE1D14E20Q93072478-675600C7-AFE3-4A06-ACF8-DF62742720AA
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Daniel Lindholm
@ast
Daniel Lindholm
@en
Daniel Lindholm
@es
Daniel Lindholm
@nl
Daniel Lindholm
@sl
type
label
Daniel Lindholm
@ast
Daniel Lindholm
@en
Daniel Lindholm
@es
Daniel Lindholm
@nl
Daniel Lindholm
@sl
prefLabel
Daniel Lindholm
@ast
Daniel Lindholm
@en
Daniel Lindholm
@es
Daniel Lindholm
@nl
Daniel Lindholm
@sl
P106
P1153
36700047500
P21
P214
17153182623026791008
P31
P496
0000-0003-3526-0614
P569
2000-01-01T00:00:00Z
P734
P735
P7859
viaf-17153182623026791008